SAN FRANCISCO – After a number of bumps along the road, confidence has returned and expectations are once again high that the gene therapy and other advanced therapies sector can finally make good on its promise to transform 21st century medicine. That enthusiasm has translated into strong IPO debuts for gene therapy companies and the FDA granting breakthrough status for multiple drug candidates in the space. Read More
SAN FRANCISCO – All those involved in the biopharma industry are always worried about something – it's in our nature. Even when the times are good we tend to fret about whether they will last. Well, bring out the anxiety pills: The 2016 U.S. presidential election is just around the corner, bringing with it a host of uncertainties about the pricing of medicines, which has reverberated into lower biotech valuations in the stock market. Read More
